Lumasiran treatment for primary hyperoxaluria type 1 led to long-term sustained urinary oxalate reduction with low rates of renal function decline, minimal kidney stone events, and improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback